weight loss drugs

The surprising applications of weight loss drugs in treating various medical conditions.

GLP-1 drugs like Ozempic, Wegovy, and Zepvound are leading a new wave of weight loss medications with surprising benefits.

These drugs, initially launched in late 2023, are showing promise in treating conditions beyond weight loss, including infertility and even Alzheimer's disease.

Julie Hyman: GLP-1 drugs, typically used for diabetes or weight loss, might have surprising applications beyond those initial purposes. Yahoo Finance's Anjalee Khemlani dives deeper.

Anjalee Khemlani: Absolutely! The latest potential use case is in infertility treatment. This is why GLP-1 drugs are back in the spotlight. We've heard a lot about these drugs lately, but it's important to focus on where the actual research is happening. Clinical trials are underway, and the FDA may eventually approve these drugs for new uses – potentially Ozempic, Wegovy, Mounjaro, and Zepbound – each tailored to a specific condition.

 

Groups drugs by company: There's exciting news about the expanding uses of GLP-1 drugs.

• Novo Nordisk:
  • Wegovy, their weight loss drug, is already approved for heart disease treatment.
  • Ozempic, their diabetes medication, is undergoing clinical trials to see if it can help with kidney disease in overweight diabetic patients.
• Eli Lilly: Their weight loss drug, Zepvound, recently showed promising results in a sleep apnea study.

Anjalee Khemlani: It's important to remember these GLP-1 drugs can have very different uses, requiring separate prescriptions. Clinical trials are ongoing across various companies and even the NIH for conditions like infertility, Alzheimer's, bone fractures, skin issues, childhood obesity, and even safety in breastfeeding mothers. This could pave the way for these mothers to resume using the drugs after childbirth.

Julie Hyman: Has any other drug shown this kind of versatility in recent history, outside of maybe 19th-century snake oil remedies?

Anjalee Khemlani: Statins used for heart health are sometimes compared for their multiple uses, but the range of potential applications for GLP-1 drugs is truly remarkable.

 

Eli Lilly's weight-loss drug, Zepbound, shows promise in treating sleep apnea.

Clinical trials revealed the drug's effectiveness in reducing sleep apnea episodes.

If the US Food and Drug Administration (FDA) approves, Zepbound could become a treatment option for sleep apnea, expanding its use beyond weight loss.

Eli Lilly's weight-loss drug shows promise for sleep apnea!

During a recent interview on Yahoo Finance, health reporter Anjalee Khemlani explained how late-stage trials revealed the drug's ability to reduce irregular breathing in sleep apnea patients.

This could lead to new treatment options beyond weight loss.

 

Eli Lilly's GLP-1 drug, Zepbound, is showing promise beyond weight loss.

The positive sleep apnea trial results add to the growing list of potential uses for GLP-1 drugs.

Lilly plans to file for an expanded label with the FDA by midyear, similar to Novo Nordisk's recent approval for cardiovascular benefits with their GLP-1 drug. Both companies are exploring even more applications, potentially including treatments for liver and kidney disease.

 

Eli Lilly takes the lead in treating sleep apnea with Zepbound.

This GLP-1 drug effectively reduced sleep apnea episodes in late-stage trials, potentially becoming the first medication of its class for this condition.

By midyear, they plan to seek FDA approval for this new use, allowing doctors to prescribe Zepbound for both weight loss (with a potential 20% reduction) and sleep apnea.